TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15750426

Group type: EXPERIMENTAL
Intervention: FDBA plus PRP
Number of subjects: 10

Group type: COMPARATOR
Intervention: FDBA plus membrane
Number of subjects: 10
Study: 12087928

Group type: EXPERIMENTAL
Intervention: Fixed combination capsule of chloroquine (100 mg) and proguanil (200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Separate tablets of chloroquine (100 mg) and proguanil (200 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fixed combination capsule of chloroquine and proguanil
Number of subjects: 12

Group type: COMPARATOR
Intervention: Separate tablets of chloroquine and proguanil
Number of subjects: 12
Study: 10480474

Group type: EXPERIMENTAL
Intervention: Morning dosing of nisoldipine ER (20 mg)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Evening dosing of nisoldipine ER (20 mg)
Number of subjects: 85
Study: 8726542

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 30822800

Group type: EXPERIMENTAL
Intervention: Multimodal pain management protocol (preoperative intravenous acetaminophen, preincision subcutaneous bupivacaine, intraoperative intramuscular ketorolac)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Multimodal pain management protocol
Number of subjects: 120
Study: 28325826

Group type: EXPERIMENTAL
Intervention: Polyphenon E (800 or 1200 mg of EGCG)
Number of subjects: 31
Study: 27275271

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with 970 nm diode laser irradiation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Topical corticosteroids (0.1% triamcinolone acetonide orabase)
Number of subjects: 24
Study: 25693307

Group type: EXPERIMENTAL
Intervention: 11 needles
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 5 needles
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 3 needles
Number of subjects: 90
Study: 22949766

Group type: EXPERIMENTAL
Intervention: Subxiphoid approach (Group 1, n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intercostal approach (Group 2, n=20)
Number of subjects: 40
Study: 18506401

Group type: EXPERIMENTAL
Intervention: Sealant (Light Bond) applied to labial surfaces
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group with no sealant
Number of subjects: 78
Study: 16430195

Group type: EXPERIMENTAL
Intervention: Peramivir 400 mg q24h
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Peramivir 200 mg q12h
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Peramivir 400 mg once daily
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Peramivir 800/400 mg once daily
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Peramivir 50 mg
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Peramivir 200 mg
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Peramivir 400 mg
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Peramivir 800 mg
Number of subjects: 288
Study: 12952257

Group type: EXPERIMENTAL
Intervention: nCPAP with heated humidification (nCPAP‐humid)
Number of subjects: 42

Group type: COMPARATOR
Intervention: nCPAP placebo humidification (nCPAP pl‐humid)
Number of subjects: 42
Study: 11098580

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leucocyte-depleted blood transfusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional allogeneic transfusion
Number of subjects: 0
Study: 8782736

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 46
Study: 1635122

Group type: EXPERIMENTAL
Intervention: Thiotepa
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 356
Study: 6364892

Group type: EXPERIMENTAL
Intervention: cyclandelate 400 mg qid
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 31464391

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (ONS) with dietary guidance
Number of subjects: 114

Group type: COMPARATOR
Intervention: Dietary guidance only (Control)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: ONS
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control
Number of subjects: 114
Study: 30015629

Group type: EXPERIMENTAL
Intervention: L-rhamnose (25 g d-1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inulin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cellulose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: L-rhamnose
Number of subjects: 10
Study: 26996096

Group type: EXPERIMENTAL
Intervention: Clinical pathway of care with guideline-based advice and exercise (up to three sessions) for low-risk participants; referral to a specialist for medium/high-risk participants
Number of subjects: 236

Group type: COMPARATOR
Intervention: Usual care provided by primary healthcare provider based on clinical judgment
Number of subjects: 236
Study: 24610876

Group type: EXPERIMENTAL
Intervention: Seropositive for HPV-16 antibodies
Number of subjects: 16656

Group type: EXPERIMENTAL
Intervention: Seropositive for HPV-18 antibodies
Number of subjects: 16656

Group type: COMPARATOR
Intervention: Seronegative women (control group)
Number of subjects: 16656
Study: 22932751

Group type: EXPERIMENTAL
Intervention: PTH 1‐34 (30 μg/kg daily intraperitoneal injections for 14 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (saline injections)
Number of subjects: 0
Study: 21221502

Group type: EXPERIMENTAL
Intervention: Food supplements
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no food supplements)
Number of subjects: 100
Study: 19453774

Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg
Number of subjects: 538

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538
Study: 16435700

Group type: EXPERIMENTAL
Intervention: Display type (icon and file name)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Display organization (arrangements with and without grouping)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Number of stimuli presented (4, 8, and 16)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Display layout complexity
Number of subjects: 10
Study: 12907547

Group type: EXPERIMENTAL
Intervention: Snoring
Number of subjects: 974
Study: 10470203

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody-based assay for TPA (TPA-M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polyclonal-based assay for TPA
Number of subjects: 0
Study: 8735197

Group type: EXPERIMENTAL
Intervention: Fluorescence polarization immunoassays (FPIA) from Abbott Laboratories for the analysis of amphetamines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of immunological assays with different antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chromatographic methods
Number of subjects: 0
Study: 1662882

Group type: EXPERIMENTAL
Intervention: Temafloxacin 200 or 400 mg once daily for 3 or 7 days
Number of subjects: 555

Group type: COMPARATOR
Intervention: Control regimen (trimethoprim/sulfamethoxazole 160 mg/800 mg, ciprofloxacin 250 mg, or norfloxacin 400 mg, each given twice daily for 7-10 days)
Number of subjects: 555
Study: 7082776

Group type: EXPERIMENTAL
Intervention: 10 mg oral tablet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg intramuscular injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg intramuscular injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10 mg intravenous injection
Number of subjects: 0
Study: 31931172

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (OAC) treatment
Number of subjects: 84521

Group type: COMPARATOR
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 84521

Group type: COMPARATOR
Intervention: Dual therapy (OAC plus antiplatelet)
Number of subjects: 84521
Study: 30053188

Group type: COMPARATOR
Intervention: PLA plus food transfers (10 kg fortified flour)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PLA only
Number of subjects: 0

Group type: COMPARATOR
Intervention: All interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: PLA plus cash transfers (750 Nepalese rupees)
Number of subjects: 0
Study: 27514611

Group type: EXPERIMENTAL
Intervention: Yoga for 3 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard medical care for 3 months
Number of subjects: 62
Study: 25231632

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (COC) users
Number of subjects: 1372

Group type: EXPERIMENTAL
Intervention: COC users with rs1799889 4G5G/5G5G genotype
Number of subjects: 1372

Group type: EXPERIMENTAL
Intervention: Haplotype G-5G-T
Number of subjects: 1372

Group type: EXPERIMENTAL
Intervention: Haplotype A-4G-G
Number of subjects: 1372
Study: 22314555

Group type: EXPERIMENTAL
Intervention: Group H (AHG present)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Group L (AHG absent)
Number of subjects: 34
Study: 20665344

Group type: EXPERIMENTAL
Intervention: Nutrition counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CES-D score
Number of subjects: 0
Study: 18654768

Group type: EXPERIMENTAL
Intervention: Escitalopram 5 mg b.i.d after 1 week
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Single-dose omeprazole 40 mg
Number of subjects: 16
Study: 16191142

Group type: EXPERIMENTAL
Intervention: Intervention group (follow-up appointment made at discharge)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard group (given referral service phone number)
Number of subjects: 250
Study: 12867221

Group type: EXPERIMENTAL
Intervention: IV gatifloxacin 400 mg QD with option for oral stepdown gatifloxacin
Number of subjects: 170

Group type: COMPARATOR
Intervention: IV ceftriaxone 1 or 2 g QD (with or without erythromycin or clarithromycin) with option for oral stepdown clarithromycin
Number of subjects: 170
Study: 11215862

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 122

Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 122
Study: 8779018

Group type: EXPERIMENTAL
Intervention: Prophylaxis study group (110 patients)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Coumadin group (part of prophylaxis study group)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Nonrandomized group (219 patients)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Overall clinical incidence
Number of subjects: 329
Study: 1645995

Group type: EXPERIMENTAL
Intervention: Ferrous fumarate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ferrous sulphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ferric pyrophosphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ascorbic acid
Number of subjects: 0
Study: 6677074

Group type: EXPERIMENTAL
Intervention: Medical check-up
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Multi-therapy
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Employed alcoholics (older)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Employment status
Number of subjects: 174
Study: 29887243

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT) with daily low-dose carboplatin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 200
Study: 28391237

Group type: EXPERIMENTAL
Intervention: Low vitamin D levels (< 50 nmol/L)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Normal vitamin D levels (≥ 50 nmol/L)
Number of subjects: 160
Study: 26690208

Group type: EXPERIMENTAL
Intervention: SIPsmartER (SSB reduction group)
Number of subjects: 292

Group type: COMPARATOR
Intervention: MoveMore (physical activity group)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: SIPsmartER
Number of subjects: 292
Study: 23204255

Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (early PN)
Number of subjects: 4640

Group type: COMPARATOR
Intervention: Late parenteral nutrition (late PN)
Number of subjects: 4640

Group type: EXPERIMENTAL
Intervention: Lowest dose of macronutrients
Number of subjects: 4640

Group type: EXPERIMENTAL
Intervention: Higher doses of macronutrients (administered parenterally or enterally)
Number of subjects: 4640

Group type: EXPERIMENTAL
Intervention: Proteins/amino acids
Number of subjects: 4640

Group type: EXPERIMENTAL
Intervention: Early combined parenteral/enteral nutrition
Number of subjects: 4640
Study: 21169833

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with stem cell rescue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy without stem cell rescue
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 18047500

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg ODT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16476679

Group type: EXPERIMENTAL
Intervention: Hysterosalpingography (HSG) followed by laparoscopy and dye
Number of subjects: 344

Group type: COMPARATOR
Intervention: Laparoscopy and dye only
Number of subjects: 344
Study: 14604250

Group type: EXPERIMENTAL
Intervention: Medtronic Affinity NT oxygenator
Number of subjects: 256

Group type: COMPARATOR
Intervention: Cobe Optima XP oxygenator
Number of subjects: 256
Study: 10707859

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ligation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sclerotherapy and Ligation
Number of subjects: 200
Study: 9315420

Group type: EXPERIMENTAL
Intervention: Femcap with nonspermicidal lubricant (K'Y gel)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Femcap with spermicide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ortho All‐Flex diaphragm with spermicide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Baseline cycles (no device)
Number of subjects: 8
Study: 8227468

Group type: EXPERIMENTAL
Intervention: Acebutolol 400 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: All drugs
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 6
Study: 3946803

Group type: EXPERIMENTAL
Intervention: Thiopental (39.5 mg/kg)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control (Fentanyl)
Number of subjects: 182
Study: 29313731

Group type: EXPERIMENTAL
Intervention: Parental guide for regulating video gaming
Number of subjects: 5864

Group type: COMPARATOR
Intervention: Control condition (no parental guide)
Number of subjects: 5864
Study: 25792707

Group type: EXPERIMENTAL
Intervention: CXB+DFMO
Number of subjects: 112

Group type: COMPARATOR
Intervention: CXB
Number of subjects: 112
Study: 1534399

Group type: EXPERIMENTAL
Intervention: 4-factor model of the McGill Pain Questionnaire Pain Rating Index (PRI)
Number of subjects: 1795

Group type: EXPERIMENTAL
Intervention: McGill Pain Questionnaire Pain Rating Index (PRI)
Number of subjects: 1795

Group type: EXPERIMENTAL
Intervention: Single subscale score from 10 PRI sensory subclasses
Number of subjects: 1795
Study: 23787379

Group type: EXPERIMENTAL
Intervention: HPS simulation group
Number of subjects: 133

Group type: COMPARATOR
Intervention: Paper and pencil case study group
Number of subjects: 133
Study: 20545389

Group type: EXPERIMENTAL
Intervention: Smoking cues
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Smoking imagery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral cues
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral imagery
Number of subjects: 60
Study: 18779282

Group type: EXPERIMENTAL
Intervention: Calorie deprivation (near calorie-free diet)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Fully fed diet
Number of subjects: 27
Study: 15692526

Group type: EXPERIMENTAL
Intervention: Clinical Trial Patient Preference Questionnaire (CTPPQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical Practice Preference Questionnaire (CPPPQ)
Number of subjects: 0
Study: 12942146

Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Number of subjects: 1
Study: 10333102

Group type: EXPERIMENTAL
Intervention: Optic disc surface smoothness (ODSS) measurement in glaucomatous eyes
Number of subjects: 90

Group type: COMPARATOR
Intervention: Optic disc surface smoothness (ODSS) measurement in normal eyes
Number of subjects: 90
Study: 9375040

Group type: EXPERIMENTAL
Intervention: Interactive low-resolution telemedicine consultation with a paediatric radiologist
Number of subjects: 24

Group type: COMPARATOR
Intervention: General radiologists' original diagnosis
Number of subjects: 24
Study: 1680893

Group type: EXPERIMENTAL
Intervention: Somatostatin infusion (250 micrograms/h for 24 hours)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Sengstaken‐Blakemore tube (balloon tamponade for 48 hours)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Combination of somatostatin and balloon tamponade
Number of subjects: 92
Study: 7282105

Group type: EXPERIMENTAL
Intervention: Azapropazone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 60
Study: 31146682

Group type: EXPERIMENTAL
Intervention: Dilution parameter (d) estimated using mixed model with IGE and d.
Number of subjects: 3

Group type: COMPARATOR
Intervention: Groups composed of two families vs. randomly composed groups.
Number of subjects: 3
Study: 28498482

Group type: EXPERIMENTAL
Intervention: Antenatal lifestyle intervention
Number of subjects: 374

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Maternal gestational weight gain
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Maternal obesity
Number of subjects: 374
Study: 26530646

Group type: EXPERIMENTAL
Intervention: Oxinium (OxZr) femoral head with conventional polyethylene (CPE)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oxinium (OxZr) femoral head with highly cross‐linked polyethylene (HXL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cobalt-chromium (CoCr) femoral head with conventional polyethylene (CPE)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cobalt-chromium (CoCr) femoral head with highly cross‐linked polyethylene (HXL)
Number of subjects: 120
Study: 23590124

Group type: EXPERIMENTAL
Intervention: Radiofrequency exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 0
Study: 18402307

Group type: EXPERIMENTAL
Intervention: Early (day 4) passive drainage
Number of subjects: 87

Group type: COMPARATOR
Intervention: Late (day 10) passive drainage
Number of subjects: 87
Study: 15564229

Group type: EXPERIMENTAL
Intervention: Leaflets with assessment and up to seven intervention sessions by an occupational therapist
Number of subjects: 168

Group type: COMPARATOR
Intervention: Leaflets describing local transport services for disabled people
Number of subjects: 168
Study: 10896067

Group type: COMPARATOR
Intervention: Intravenous secretin (2 U/kg) plus placebo (Group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous secretin (2 U/kg) plus cholecystokinin (0.02 microg/kg) (Group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 40
Study: 9378668

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment (Nux vomica D200, Okoubaka D3, Tuberculinum D200, Barium jodatum D4, Barium jodatum D6)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 8317516

Group type: EXPERIMENTAL
Intervention: OC3 (35 micrograms ethinyl estradiol and 0.5 mg norethindrone)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: OC2 (35 micrograms ethinyl estradiol and 1.0 mg norethindrone)
Number of subjects: 192
Study: 2941051

Group type: EXPERIMENTAL
Intervention: Daktacort (2% miconazole base and 1% hydrocortisone)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Miconazole (2% miconazole base)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Hydrocortisone (1% hydrocortisone)
Number of subjects: 70
Study: 31859725

Group type: EXPERIMENTAL
Intervention: 2-octyl-cyanoacrylate
Number of subjects: 79

Group type: COMPARATOR
Intervention: Nylon suture
Number of subjects: 79
Study: 29103340

Group type: EXPERIMENTAL
Intervention: Pegberon plus ribavirin
Number of subjects: 770

Group type: COMPARATOR
Intervention: Pegasys plus ribavirin
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Baseline ATA positive patients
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Baseline ATA negative patients
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Baseline NAb positive patients
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Baseline NAb negative patients
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Induced ATA positive patients
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Sustained ATA negative patients
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Pegberon
Number of subjects: 770

Group type: COMPARATOR
Intervention: Pegasys
Number of subjects: 770
Study: 26751473

Group type: EXPERIMENTAL
Intervention: NutriRice
Number of subjects: 2440

Group type: EXPERIMENTAL
Intervention: URN
Number of subjects: 2440

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2440
Study: 24528935

Group type: EXPERIMENTAL
Intervention: Combination of hyaluronate and diquafosol
Number of subjects: 105

Group type: COMPARATOR
Intervention: Sodium hyaluronate
Number of subjects: 105

Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 105

Group type: COMPARATOR
Intervention: Diquafosol tetrasodium
Number of subjects: 105
Study: 22238339

Group type: EXPERIMENTAL
Intervention: DepoFoam bupivacaine (133 or 266 mg)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: bupivacaine HCl (75 mg)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: bupivacaine HCl (200 mg)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: DepoFoam bupivacaine (532 mg)
Number of subjects: 94
Study: 19279561

Group type: EXPERIMENTAL
Intervention: NIC gum treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CYP2A6 genotype group
Number of subjects: 0
Study: 17192761

Group type: EXPERIMENTAL
Intervention: STS 6 mg/24 hr
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15923689

Group type: EXPERIMENTAL
Intervention: Zinc and copper supplementation (40 mg of zinc sulfate and 5 mg of copper sulfate in ORS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (50 mg of standard ORS powder in ORS)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Zinc and copper supplementation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200